The data from the booster and phase 3 study on the anti-Covid vaccine developed by Sanofi together with GSK are positive. This was announced by the two companies, ready to present the data and then seek approval in Europe and the United States.
The recombinant adjuvanted Sanofi-Gsk vaccine induced robust immune responses – explain the two companies in a joint note – with a favorable safety profile in multiple contexts. In participants who had already had two doses of already licensed mRna or adenovirus vaccines, booster with the Sanofi-Gsk product induced a significant increase in neutralizing antibodies from 18 to 30 times. When the Sanofi-Gsk vaccine was used as a primary course with two doses followed by a booster, neutralizing antibodies increased 84 to 153 times compared to pre-booster levels.
#Covid #vaccine #Sanofi #Gsk #ready #approval